TD Cowen restated their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research note published on Tuesday morning, Benzinga reports.
Several other research firms also recently weighed in on FUSN. B. Riley downgraded Fusion Pharmaceuticals from a buy rating to a neutral rating and boosted their target price for the company from $13.00 to $23.00 in a research report on Wednesday, March 20th. William Blair downgraded Fusion Pharmaceuticals from an outperform rating to a market perform rating in a research report on Tuesday, March 19th. Raymond James reissued a market perform rating on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Royal Bank of Canada reissued a sector perform rating and set a $21.00 target price (up previously from $16.00) on shares of Fusion Pharmaceuticals in a research report on Wednesday, March 20th. Finally, SVB Leerink reissued a market perform rating and set a $21.00 target price (up previously from $17.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Thirteen analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Fusion Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $20.25.
Check Out Our Latest Stock Analysis on Fusion Pharmaceuticals
Fusion Pharmaceuticals Stock Performance
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative return on equity of 46.59% and a negative net margin of 4,136.55%. As a group, equities analysts anticipate that Fusion Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Fusion Pharmaceuticals
Hedge funds have recently bought and sold shares of the business. Yarbrough Capital LLC purchased a new stake in shares of Fusion Pharmaceuticals in the 4th quarter worth $739,000. Forefront Analytics LLC lifted its holdings in shares of Fusion Pharmaceuticals by 67.8% in the 3rd quarter. Forefront Analytics LLC now owns 33,685 shares of the company’s stock worth $88,000 after buying an additional 13,610 shares during the period. Avidity Partners Management LP lifted its holdings in shares of Fusion Pharmaceuticals by 1.4% in the 3rd quarter. Avidity Partners Management LP now owns 5,781,850 shares of the company’s stock worth $15,033,000 after buying an additional 81,850 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Fusion Pharmaceuticals in the 4th quarter worth $80,000. Finally, Federated Hermes Inc. lifted its holdings in shares of Fusion Pharmaceuticals by 0.5% in the 3rd quarter. Federated Hermes Inc. now owns 10,683,789 shares of the company’s stock worth $27,778,000 after buying an additional 50,000 shares during the period. Institutional investors own 72.85% of the company’s stock.
Fusion Pharmaceuticals Company Profile
Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.
Featured Stories
- Five stocks we like better than Fusion Pharmaceuticals
- How to Invest in the FAANG Stocks
- Silicon Motion Proves That AI in Motion Stays in Motion
- How to buy stock: A step-by-step guide for beginnersÂ
- Undervalued UnitedHealth Group Won’t Be For Long
- What is Forex and How Does it Work?
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.